Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Suzhou Zion Out-Licenses Brain-Penetrating HER2 Candidate to Roche in $680 Million Deal

publication date: May 9, 2023

Suzhou Zion Pharma out-licensed ex-China global rights for its lead HER2 candidate to Roche in a $680 million agreement ($70 million upfront). ZN-A-1041 is an oral selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2) that was designed to penetrate the blood-brain-barrier. Up to 50% of patients with HER2-positive metastatic breast cancer will develop brain metastasis over the course of the disease. Zion is conducting a Phase 1 trial of the candidate in China and the US, with trial details expected at the poster sessions during the ASCO meeting next month. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital